Elucidation on the In Vivo Activity of the Bivalent Opioid Peptide MACE2 Against Several Types of Chronic Pain

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2024 Nov 18

PMID 39554412

Authors

Azzurra Stefanucci

Lorenza Marinaccio

Stefano Pieretti

Joseph A Mancuso

Carrie Stine

John M Streicher

Adriano Mollica

Affiliations

Soon will be listed here.

Abstract

Biphalin is a bivalent μ/δ opioid receptor agonist showing a promising therapeutic profile with reduced side effects, but as a peptide is limited by poor metabolic stability and blood-brain barrier penetration. To improve these features, we developed the ligand and showed initial in vivo efficacy. To further explore the druggability of this ligand, in this report, we tested metabolic stability in human plasma, receptor engagement by 3 different routes of administration using the tail-flick test, and efficacy in 2 different pathological and chronic pain models. We found that had high stability in plasma and could produce target engagement and a tail flick response. We also showed that had high analgesic efficacy in CIPN but no efficacy in paw incision. Together, these findings suggest that has improved metabolic stability and brain penetration in vivo, prompting further development in clinical testing.

References

Shen K, Crain S . Biphalin, an enkephalin analog with unexpectedly high antinociceptive potency and low dependence liability in vivo, selectively antagonizes excitatory opioid receptor functions of sensory neurons in culture. Brain Res. 1995; 701(1-2):158-66. DOI: 10.1016/0006-8993(95)00999-1. View

Gomes I, Jordan B, Gupta A, Trapaidze N, Nagy V, Devi L . Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J Neurosci. 2000; 20(22):RC110. PMC: 3125672. View

Kroenke K, Krebs E, Bair M . Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009; 31(3):206-19. DOI: 10.1016/j.genhosppsych.2008.12.006. View

Sutters K, Miaskowski C, Taiwo Y, Levine J . Analgesic synergy and improved motor function produced by combinations of mu-delta- and mu-kappa-opioids. Brain Res. 1990; 530(2):290-4. DOI: 10.1016/0006-8993(90)91297-t. View

Mollica A, Pinnen F, Costante R, Locatelli M, Stefanucci A, Pieretti S . Biological active analogues of the opioid peptide biphalin: mixed α/β(3)-peptides. J Med Chem. 2013; 56(8):3419-23. PMC: 3942533. DOI: 10.1021/jm301456c. View

Dietis N, McDonald J, Molinari S, Calo G, Guerrini R, Rowbotham D . Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505). Br J Anaesth. 2011; 108(2):262-70. DOI: 10.1093/bja/aer377. View

Horan P, Mattia A, Bilsky E, Weber S, Davis T, Yamamura H . Antinociceptive profile of biphalin, a dimeric enkephalin analog. J Pharmacol Exp Ther. 1993; 265(3):1446-54. View

Keresztes A, Olson K, Nguyen P, Lopez-Pier M, Hecksel R, Barker N . Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium/calmodulin-dependent protein kinase II signaling. Pain. 2021; 163(1):146-158. PMC: 8688156. DOI: 10.1097/j.pain.0000000000002320. View

DSouza R, Langford B, Wilson R, Her Y, Schappell J, Eller J . The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain. Expert Opin Pharmacother. 2022; 23(7):775-789. DOI: 10.1080/14656566.2022.2060741. View

10.

Lei W, Vekariya R, Ananthan S, Streicher J . A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models. J Pain. 2019; 21(1-2):146-160. PMC: 6906261. DOI: 10.1016/j.jpain.2019.05.017. View

11.

Dietis N, Niwa H, Tose R, McDonald J, Ruggieri V, Filaferro M . In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505. Br J Pharmacol. 2018; 175(14):2881-2896. PMC: 6016625. DOI: 10.1111/bph.14199. View

12.

Berge O . Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol. 2011; 164(4):1195-206. PMC: 3229757. DOI: 10.1111/j.1476-5381.2011.01300.x. View

13.

Stefanucci A, Carotenuto A, Macedonio G, Novellino E, Pieretti S, Marzoli F . Cyclic Biphalin Analogues Incorporating a Xylene Bridge: Synthesis, Characterization, and Biological Profile. ACS Med Chem Lett. 2017; 8(8):858-863. PMC: 5554896. DOI: 10.1021/acsmedchemlett.7b00210. View

14.

Stefanucci A, Dimmito M, Molnar G, Streicher J, Novellino E, Zengin G . Developing Cyclic Opioid Analogues: Fluorescently Labeled Bioconjugates of Biphalin. ACS Med Chem Lett. 2020; 11(5):720-726. PMC: 7236251. DOI: 10.1021/acsmedchemlett.9b00569. View

15.

Varga B, Streicher J, Majumdar S . Strategies towards safer opioid analgesics-A review of old and upcoming targets. Br J Pharmacol. 2021; 180(7):975-993. PMC: 9133275. DOI: 10.1111/bph.15760. View

16.

Schwarz A, Keresztes A, Bui T, Hecksel R, Pena A, Lent B . Terpenes from Cannabis sativa induce antinociception in a mouse model of chronic neuropathic pain via activation of adenosine A 2A receptors. Pain. 2024; 165(11):e145-e161. PMC: 11511650. DOI: 10.1097/j.pain.0000000000003265. View

17.

Mollica A, Davis P, Ma S, Porreca F, Lai J, Hruby V . Synthesis and biological activity of the first cyclic biphalin analogues. Bioorg Med Chem Lett. 2005; 16(2):367-72. DOI: 10.1016/j.bmcl.2005.09.080. View

18.

HEYMAN A, WILKINSON W, Hurwitz B, Helms M, Haynes C, Utley C . Early-onset Alzheimer's disease: clinical predictors of institutionalization and death. Neurology. 1987; 37(6):980-4. DOI: 10.1212/wnl.37.6.980. View

19.

Lei W, Mullen N, McCarthy S, Brann C, Richard P, Cormier J . Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain. J Biol Chem. 2017; 292(25):10414-10428. PMC: 5481554. DOI: 10.1074/jbc.M116.769489. View

20.

Podolsky A, Sandweiss A, Hu J, Bilsky E, Cain J, Kumirov V . Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. Life Sci. 2013; 93(25-26):1010-6. PMC: 3962292. DOI: 10.1016/j.lfs.2013.09.016. View